Platinum chemotherapy in HRD tumours
DNA-crosslinking chemotherapy is especially effective in tumours that cannot repair double-strand breaks.
Carboplatin raises pCR in TNBC (GeparSixto, BrighTNess) with greater benefit in BRCA/HRD; platinum sensitivity defines the treatable ovarian cancer population.
Pages like this
not linked directly; found by shared links- PersonAndrew Tutt
Shares Platinum agents, Carboplatin, BRCA1 / BRCA2 (HRD), Triple-negative breast cancer (TNBC).
- IdeaA strategic reserve of essential generic cancer drugs to end recurring shortages
Shares Platinum agents, Carboplatin.
- IdeaGo back to families of women who died of ovarian cancer and offer BRCA testing
Shares BRCA1 / BRCA2 (HRD), Ovarian cancer.
- IdeaA non-profit manufacturer for generic cancer drugs in chronic shortage
Shares Platinum agents, Carboplatin.
- PersonAlan Ashworth
Shares BRCA1 / BRCA2 (HRD), Ovarian cancer, Triple-negative breast cancer (TNBC).
- PersonSabine Linn
Shares BRCA1 / BRCA2 (HRD), Triple-negative breast cancer (TNBC).
- PersonLeif W. Ellisen
Shares BRCA1 / BRCA2 (HRD), Triple-negative breast cancer (TNBC).
- TechnologyPARP PET
Shares DNA damage response & homologous recombination, Ovarian cancer, Triple-negative breast cancer (TNBC).